C5orf55 Inhibitors
C5orf55 Inhibitors represent a diverse class of chemicals designed to modulate the activity of the C5orf55 protein. The selected compounds in the table above target various cellular signaling pathways associated with C5orf55 activation. Lapatinib, for instance, interferes with phosphorylation, potentially hindering C5orf55 function. PD-0325901 and U0126 focus on the MAPK pathway, while Wortmannin and LY294002 disrupt the PI3K/AKT pathway, both intricately linked to C5orf55 signaling. SB-203580 and SP600125 impact the JNK and p38 MAP kinase pathways, respectively, offering additional avenues for C5orf55 modulation. Sorafenib and VX-680, multi-kinase inhibitors, target various kinases in pathways associated with C5orf55. SB-431542 inhibits the TGF-β receptor, and Selumetinib disrupts the MAPK/ERK pathway, further diversifying the strategies to potentially influence C5orf55 activity. This chemical class showcases a targeted approach, aiming to interfere with key cellular pathways intricately connected to C5orf55, providing a foundation for potential future studies exploring the functional aspects of this intriguing protein.
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Lapatinib | 231277-92-2 | sc-353658 | 100 mg | $420.00 | 32 | |
Lapatinib is a tyrosine kinase inhibitor that can potentially inhibit C5orf55 by disrupting its phosphorylation. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
A PI3-kinase inhibitor, Wortmannin, may interfere with C5orf55 signaling by disrupting the PI3K/AKT pathway. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $64.00 $246.00 | 136 | |
U0126 inhibits MEK1/2, offering a possible means to modulate C5orf55 activity by affecting the MAPK pathway. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
SB-203580 targets p38 MAP kinase, potentially influencing C5orf55 by disrupting signaling cascades. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY294002 is a PI3K inhibitor that might hinder C5orf55 activation by interfering with the PI3K/AKT pathway. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
An mTOR inhibitor, Rapamycin can potentially modulate C5orf55 by affecting the mTOR signaling pathway. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 inhibits JNK, possibly impacting C5orf55 activity through interference with the JNK signaling pathway. | ||||||
SB 431542 | 301836-41-9 | sc-204265 sc-204265A sc-204265B | 1 mg 10 mg 25 mg | $82.00 $216.00 $416.00 | 48 | |
SB-431542 is a TGF-β receptor inhibitor, potentially affecting C5orf55 by disrupting TGF-β-associated pathways. | ||||||
Sorafenib | 284461-73-0 | sc-220125 sc-220125A sc-220125B | 5 mg 50 mg 500 mg | $57.00 $100.00 $250.00 | 129 | |
Sorafenib, a multi-kinase inhibitor, may influence C5orf55 by targeting various kinases in associated pathways. | ||||||
Tozasertib | 639089-54-6 | sc-358750 sc-358750A | 25 mg 50 mg | $62.00 $87.00 | 4 | |
VX-680 inhibits Aurora kinases, providing a potential means to modulate C5orf55 activity through kinase pathways. | ||||||